Thorne's Quercetin Phytosome Trial for Metabolic Health Was Terminated Early

Quercetin is one of the most abundant dietary flavonoids, found in onions, apples, berries, and leafy greens. Decades of cell and animal studies have linked it to anti-inflammatory, antioxidant, and senolytic effects. Translating those findings into robust human clinical evidence, however, has proven difficult — and this trial illustrates that challenge directly.

Thorne HealthTech designed a 90-day interventional study to test Quercetin Phytosome, a proprietary formulation that binds quercetin to phospholipids to enhance intestinal absorption. The rationale came from a computational model that predicted quercetin could produce measurable improvements in metabolic biomarkers. Enrolled participants were instructed to keep diet, exercise, and other lifestyle variables stable throughout, allowing researchers to attribute changes in blood markers specifically to the supplement.

The primary outcomes included LDL cholesterol, fasting blood glucose, liver enzymes, kidney function markers, immune indicators, and a composite 'metabolic age' score calculated from those values. Questionnaires were designed to capture subjective quality-of-life improvements and verify protocol compliance. The study represented a proof-of-concept effort — if successful, it would have provided human validation for the computational model's predictions and potentially opened new clinical applications for quercetin.

The trial was terminated before completion, and no results have been published. The registry does not specify whether termination was due to enrollment difficulties, safety concerns, business decisions, or other factors. Without efficacy or safety data, the computational model's predictions remain untested in this population.

For clinicians and health-conscious consumers, this outcome is a reminder that promising preclinical and computational findings frequently fail to reach publication as clinical evidence. Quercetin supplementation remains popular, but high-quality human RCT data on metabolic outcomes is still limited. The enhanced bioavailability angle of phytosome formulations also warrants independent investigation.